Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | LIPE | Q05469 | 3/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328636 | 0.82 | DGAT1 (0.45) | L3MBTL1MAOB | |
| SCHEMBL3209995 | 0.80 | LMNA (0.42) | L3MBTL1LMNAMRGPRX4PKMHSD17B10 | |
| SCHEMBL10304907 | 0.78 | BRD4 (0.53) | MCL1PTGESL3MBTL1BRD4LMNA | |
| SCHEMBL15328983 | 0.78 | RXRA (0.41) | MRGPRX4MAOBLIPE | |
| SCHEMBL18161383 | 0.76 | L3MBTL1 (0.50) | MCL1PTGESL3MBTL1BRD4LMNA | |
| SCHEMBL19141123 | 0.76 | DGAT1 (0.43) | LMNAMAOB | |
| SCHEMBL261662 | 0.73 | CXCR2 (0.39) | LIPE | |
| SCHEMBL8620460 | 0.72 | MCL1 (0.51) | MCL1PTGESL3MBTL1BRD4LMNA | |
| SCHEMBL31409564 | 0.72 | MAOB (0.53) | MAOB | |
| SCHEMBL17129613 | 0.72 | MAOB (0.59) | L3MBTL1MRGPRX4MAOBHTTNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838881-B1 | ISOINDOLONE DERIVATIVES | ABBVIE INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9776990-B2 | Isoindolone derivatives | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150111890-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. | 2015-04-23 | — | — | US | disclosed |
| EP-2850071-A1 | ISOINDOLONE DERIVATIVES | AbbVie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2838881-A1 | ISOINDOLONE DERIVATIVES | AbbVie Inc. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013155695-A1 | ISOINDOLONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013158952-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281450-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111890-A1 | ISOINDOLONE DERIVATIVES | CYP11B1, HSD17B7, CYP4A11 | MCL1 1822/4885PTGES 229/4885L3MBTL1 2467/4885 |
| US-20130281450-A1 | ISOINDOLONE DERIVATIVES | CYP11B1, HSD17B7, CYP4A11 | MCL1 1716/4885PTGES 232/4885L3MBTL1 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.